A low molecular weight heparin (enoxaparin, mean molecular weight -4,400) was separated by gel chromatography into eight different fractions with a narrow distribution around the following mean molecular weights : L,800, 2,400, 2, 900, 4,200, 6,200, 8,600, 9,800 and 11,000. We compared the influence of enoxaparin on the generation of thrombin in plasma to that of the eight fractions.
part to their anti-factor Xa activity. From there it was a small step to surmise that LMWHs with a high ratio of anti-factor Xa-to antithrombin activity could make better antithrombotics than conventional. unfractionated heparins (7) .
The inhibitory actions of a heparin measured on isolated factors do not, however, necessarily directly reflect its activities in the complex medium of plasma (8) (9) (10) (11) . In order to study the effects of heparins under the conditions prevailing in clotting plasma, a method has been developed in our laboratory that allows the calculation of the conversion rate of prothrombin, independent of the simultaneous breakdown of the thrombin generated (8) . BV this approach it could be shown that: 1. Unfractionated heparin (UFH) acts mainly by enhancing thrombin breakdown, its effect on the inhibition of prothrombinase in the extrinsic pathway is of minor i.mportance (12) . 2. The synthetic pentasaccharide (PS) that represents the AT IIIbinding site of heparin (13), and that does not catalyse direct inhibition of thrombin (14), unlike UFH does inhibit prothrombinase via its action on inhibition of free factor Xa (15). 3. Most low molecular weight heparins (LMWHs) act rather like standard heparin, in that they have a minor influence on the prothrombinase activity in plasma, even though the anti-factor Xalantithrombin ratio is reported to be high (16) . One of the LMWH preparations that we studied, PK 10169 or enoxaparin, caused a relatively high inhibition of prothrombin conversion. This has previously been explained as being caused by a high proportion of pentasaccharide like material (17) . In this study we want to establish what material in enoxaparin is responsible for its over-all action on blood coagulation. To this end we prepared from enoxaparin eight fractions with largely different average molecular weight (MW) and a narrow MW distribution. We studied the anti-thrombin and anti-prothrombinase properties as a function of the HAM and the ACLM content of these fractions.
Materials and Methods

Materials
Three batches of the low molecular weight heparin enoxaparin (88.145.02; 89.009.01;89.037 01) were supplied by Rh6ne-Poulenc Rorer: They were prepared from heparin by chemical B-elimination. Three runs were performed with different batches of heparin. The average MW of the three batches of enoxaparin were around 4,400, 4,500, and 4,500 respectively. Their anti-factor Xa activities (18, 19) were 115, I20 and 108.5 IU/mg. Their activity in the European pharmacopoeia method (i. e. an activated partial thromboplastin time in sheep plasma) was 56.3, 66 and 57 lUlmg respectively From one of these batches (88.145.02) eight fractions with narrow MW distribution were obtained (see Methods).
The chromogenic substrate for thrombin, H.D-Phe-Pip-Arg-pNA (S-2238), was obtained from Kabi, Sweden. Kaolin (Kaolin l6ger) was provided by B L B. Laboratoires du Bois de Boulogne (Puteaux, France).
Buffer A: 0.05 M Tiis-HCl, 0 1 M NaCl, 0.5 mg/ml albumin, pH 7.35.
Buffer B: 0.05 M Tiis-HCl, 0.1 M NaCl, 0.5 mg/ml albumin with 20 mM EDTA at pH 7.90. Plasma increase can subsequently be plotted as a function of the heparin concentration (in pglml). Upon addition of increasing amounts of heparin, the fluorescence of AT III increases proportionally with the heparin concentration until the equivalence point has been reached The concentration of the heparin fraction at the inflection point (in pglml), contains the number of binding sites present in the AT III added, i. e. 0.5 pM It should be noted that this determination is independent of the magnitude of the fluorescence change, i.e. independent of possible changes of fluorescence with the chainlength of the heparin The AT III itself has been titrated with synthetic pentasaccharide that is assumed to contain 100% high affinity material. In this way one obtains the molar concentration of binding sites per mg of heparin Knowing the MW of the heparin we can then calculate the percentage of high affinity molecules in the heparin preparation. The titration was carried out on a SLM Aminco SPF-500 C spectrofluorometer.
Rate Constants of Inactivation of Endogenous Thrombtn
Defibrinated plasma (120 pl) is mixed with bufi'er A (14 pl), and prewarmed for 5 minutes at 37' C. Thrombin generation is started by the addition of 30 pl of thromboplastin dilution Two minutes after the peak activity of thrombin, 6 pl of a 10 mg/ml Soybean Tiypsin Inhibitor (SBTI) solution (8) , is added together with 10 pl of buffer that contains the heparin to be tested. At suitable intervals after this addition 10 pl aliquots of the incubation mixture are transferred to cuvettes containing 0.2 mM of 5-2238 in 490 pl of buffer B, to measure residual thrombin activity. After 120 s, the reaction in the cuvette is stopped by adding 300 pl of concentrated acetic acid. The pseudo-first order rate constant of inhibition Blood from ten healthy donors was collected on 0.13 M trisodium citrate; nine parts of blood to one part of citrate solution. A first and a second centrifugation were done at 15" C, during 15 min at 3,000 x g, and a third centrifugation was done at 4" C, for t hour at 23,000 x g The platelet fiee plasma thus obtained was stored at -80" C. It was checked that the clotting factors and the antiproteases were in the normal range. Defibrinated plasma was obtained by mixing an aliquot of plasma with 1 : 50 volume of a reptilase solution, letting a clot form for 5 min at37' C, and keeping the clotted plasma at 4' C for 10 min The fibrin formed was discarded by winding it on a small plastic spatula. As it was previously shown, the concentration of factors II, VII, VIII, IX, X, XI and XII does not change significantly by the reptilase treatment (8) .
Proteins
Reptilase was obtained from Boehringer Mannheim (Mannheim, Germany) and dissolved according to the instructions of the manufacturer. Soybean Tiypsin Inhibitor, (batch No. 43 F 8000) was obtained from Sigma (St. Louis, MO). Staphylocoagulase was obtained from Laboratoires Stago (Asnidres, France) and reconstituted according to the instructions of the manufacturer. Human AT III was a gift of Prof. H. Goudemand (Lille, France) It had been prepared by polyethylene glycol precipitation of barium citrate-adsorbed plasma and affinity chromatography on a heparin-sepharose column (20) . The AT III was subsequently freed of remaining heparin by ion exchange chromatography (21) . Its activity was assessed by titration with active site titrated factor Xa (22) . Human brain thromboplastin was prepared according to Owren and Aas (23) . Before use it was diluted with buffer A containing 0 1 M Ca2+ so as to clot in 70-80 s a mixture ot 120 1tl of plasma, 30 pl of thromboplastin and 30 pl of buffer A.
Methods
Heparin Fractionation
From one of the enoxaparin batches (88.145.02) eight fractions with narrow molecular weight distribution were obtained by gel permeation chromatography on ACA 202 and ACA 54 (Tables 1 and 2 ). The mobile phase was 0 33 M NaCl. The average molecular weight of the fractions obtained (N6 to N36) was determined by High Performance Size Exclusion Chromatography (HPSEC) coupled with Laser Light Scattering. In addition, we estimate the average number of disaccharidic units per chain by 13C NMR analysis Q ). The narrow elution profiles and the ratio of weight average to number average molecular weights of close to unity indicated a limited degree of polydispersity. HPSEC was performed on a system that consists of a Gilson 302 pump, an RID 6 A differential refractometer (Shimadzu) and an SF UV detector (Kratos). Aqueous solutions of enoxaparin at 10 mg/ml were analysed on a two-column system (TSK G 3000 SW-30 x 0.75 cm and Lichrosorb 100 diol 25 x 0.75 cm). The mobile phase (0.3 M phosphate buffer, pH 7) was used at flow rate 0.75 ml/min. Due to the narrow distribution of the fractions. they were used to calibrate the chromatographic system used subsequently for the determination of the MW of enoxaparin. This was determined by HPSEC coupled with refractometry.
Fluorescence Measurements
The molar concentrations of the HAM in each isolated fraction were determined by a stoichiometric titration of AT III (0.5 pM) in buffer (Tiis HCI 50 mM, NaCl 0.1 M, pH 7.5) as described in ref. (25) . Briefly, the binding of a heparin fraction to Antithrombin III results in an increase of the tryptophan fluorescence of the protein (excitation at 285 nm, emission at 345 nm; ref. (Table 2) , and the molecular weight from the data shown in Thble 1 Table 2 AT III binding material of the enoxaparin fiactions first order rate constants by calculating the increase of ft1 per pg of heparin. k2 appeared not to be dependent on the amount of heparin added.
Thrombin Generation in Plasma 240 ytl of defibrinated plasma is supplemented with 60 pl of buffer A, containing heparin at the desired concentration and incubated for 5 min at 37" C. Ar zero time, thrombin generation is started by the addition of 60 pl of a solution containing 100 mM of CaCl2, and a trigger of coagulation. For the extrinsic system this is human brain thromboplastin, as described in the previous section For the intrinsic system, 1 pM phospholipid and 0.025 mg kaolin (final concentration). At intervals, a 10 pl aliquot of the mixture is sampled into a disposable plastic cuvette containing buffer and chromogenic substrate, as described above. The optical density is mcasured at 405 nm. The amidolytic activities in the plasma samples are calculated from the O.D., and expressed as the equivalent concentration of thrombin (in nM), according to a reference curve obtained with active site titrated purified human cr-thrombin. From the curves of amidolytic activity the thrombin concentrations were obtained as previously described (8) . Of each heparin species a series of concentrations was tcsted so as to find that one (IC25) that inhibits the peak of generated thrombin by 25%. The unconventional IC25 was choosen rather than IC50 in order to allow comparison with the IC25 of prothrombinase (see results section).
Prothrombinase Activity in Plasma
The generation of prothrombinase activity is calculated from the amidolytic activity currr'e thrombin generation as described previously (8) . Briefly, the observed amidolytic activity is the sum of thrombin activity and the partial activity of o2M-thrombin complex. The rate of thrombin generation at any moment is the sum of two processes: a) the conversion of prothrombin into thrombin by prothrombinase and b) the decay of thrombin by the action of plasma protease inhibitors. The rate of inhibition of thrombin at any time can be calculated from the concentration of thrombin at that moment and the pseudo-first oder rate constant of thrombin inhibition by antithrombin III (t1) and n2-macroglobulin (ft2).
Heporin Concentrollon, pg / ml *) The activities are expressed in min t (pg/-t)-t except for the last column that is in min 1 nM 1 of thrombin generated in plasma is calculated by fitting the data to C,: Cn + Coe t't, where C, is the thrombin activity at time /, Cp is the steady endJevel activity, Co + CR is the amidolytic activity at the time of SBTI addition. The observed decay constant is thc sum of two constants, k : kr 1-kzl k1 is the AI Ill-dependent decay constant of inhibition of thrombin, k2 is the decay constant of inhibition of thrombin by o2-macroglobulin (o2-M).
The ratio of klto k2 is determined as the ratio of the amounts of thrombin complexed with AT III and o2-M as described previously (8) . From their sum and their ratio the constants are calculated k1 in all instances is lineary dependent upon the heparin concentration, so the second order rate constants of thrombin inhibition could be obtained from the pseudo-
The rate of prothrombin activation (prothrombinase activity) then can be calculated from the observed rate of generation of amidolytic activity and the rate of thrombin inhibition. Table 1 summarises the data obtained from the physicochemical characterisation of the fractions. The ratio of near unity of the weight average to the number average molecular weight demonstraies the nuiro* distribution of the MW of these fractions' Also in Thble 1 one finds the chainlength as calculated from the HPLC data on basis of a mean MW of 300 per monosaccharide unit, as well as the chainlength obtained from the 13C NMR data' From from HPLC profiles. The titration of AT III with the heparins permitted to calculate the active concentration of heparin at the equivalence point' heparin molecule.
Results
Physicochemical Properties and AT III Affinity of the Fractions
The Specific Antithrombin Activity
The effect of increasing concentrations of the heparins on the pseudo-first order decay constant of endogenous thrombin was determined. For each of the preparations the constant increased Thrombin linearly with the concentration of the heparin (Fig.3) . From the slope of these lines we determined the specific activity of the heparins (Table 3) . We define the specific acitivty of a heparin as the increase of the decay constant of thrombin in plasma per pgl ml of heparin. (It can also be expressed per nanomole in those preparations of well defined molecular weight. A specific antiiactor Xa activity can be defined analogously). Reasoning that the activity is caused by molecules with a high affinity to AT III and above the critical chainlength of 18 monosaccharide units, we calculated the specific activities of both the HAM and the ACLM in the fractions. The specific activity of enoxaparin is 1.050 min-l pg-1 ml (mean of three batches), which is close to the value of 1.110 min-1 pg-r ml) calculated from previous data (17)' This amounts to 7.500 min 1 per pglml of HAM and 3I'250 per pglml of ACLM.
The Overall Inhibition of the Thrombin Peak
The inhibitory activity of the heparin on the formation of free thrombin in clotting plasma is an over-all effect that can be due to both an increased decay of thrombin and an decreased prothrombin conversion. We can calculate (see methods section and ref ' 8) what part of the over-all inhibition is to be attributed to inhibition of prothrombin conversion and what part to the acceleration of thrombin decay. This calculation is based on the observed thrombin activities and requires a minimum of -20% of residual thrombin activity to maintain the required accuracy. Half total inhibition of prothrombin conversion often occurs at > 80% inhibition of the thrombin peak. We therefore determined the concentration of heparin necessary to obtain 25'/" of the prothrombinase activity, and compared it to the heparin concentration that causes 257o inhibition of the thrombin peak (IC25' Table  4 ). This was done both in the extrinsic-and the intrinsic system (Fig. a) . The results were again expressed in terms of HAM' We did not present the results in t..rms of ACLM, since prothrombinase inhibition is not necessarily confined to heparin molecules longer than the critical chainlength It was systematically observed that heparin does not cause a prolongation of the lag-phase in the extrinsic system but all fractions studied prolong the lag-phase in the intrinsic pathway (Fig. s) .
Discussion
Heparins need a chainlength of 18 saccharides or more in order to catalyse thrombin breakdown but the anti-factor Xa activity requires only a pentasaccharide sequence (13). It is often suggested that the smaller a heparin is, the more it exhibits a specific anti-factor Xa activity (2-6). In the usually highly disperse LMWH preparations this can mean either of two things. First, is it possible that in heparin preparations with low mean molecular weight, the proportion of molecules with uniquely anti-factor Xa properties is high. Second there might be a gradual change of properties with the chainlength i. e. the heparins become proportionally more efficient thrombin inhibitors with increasing chainlength. There are no quantitative data available from the literature on the variation of the catalytic activity with the chainlength under circumstances comparable to those where heparins exert their therapeutic action, i. e. in plasma in the presence of Ca2+ ions, although it has been well documented that the effect of Ca2* is important (2729). In this study, it was our aim to determine the effect of heparin chainlength on thrombin breakdown and prothrombin conversion under circumstances comparable to those in which heparins exhibit their therapeutic action, i. e. in clotting plasma. To this end we prepared a series of subfractions of the LMWH enoxaparin. These fractions appear to have a narrow molecular weight distribution, the ratio of weight average and number average molecular weight is near unity and the chainlength obtained by dividing the molecular weight through the mean molecular weight of one monosaccharide unit (300) gives a figure near to the number obtained from NMR measurements. We therefore think that the fractions are reasonably homogeneous with respect to their chainlength.
They remain heterogeneous as to chemical composition. This already follows from the observation that the relative amount of material with high affinity to AI III decreases with decreasing molecular weight. This is a logical consequence of the LMWH preparations being obtained by random fragmentation of conventional heparin. With an increasing of cleavages the mean molecular weight of the resulting product drops, but also the probability increases that the high affinity pentasaccharide region is severed so that the remaining molecule looses its HAM character. This automatically implies that the MW distribution of the HAM fraction within a LMWH cannot be the same as that of the total fraction. It must be shifted to the higher MW ranges. This again implies that it must be possible that isolation of a narrow zone of higher MW material from a LMWH will cause a relative gain of high affinity material, which explains that in some fractions the HAM content can be higher than in the original material.
The Specffic Antithrombin Activity
To judge the effect of the molecular size on the activity, one should express the activities on basis of the amount of active material, i. e. in terms of high affinity material (HAM) and, when anti-thrombin activities are concerned in terms of hieh affinitv material above the critical chainlength of 18 monosaccharide units (ACLM). In another study (30) we compared the specific activities of an ultralow-, low-, and middle molecular weisht fractions of another LMWH (CY2l6) and the isolated high affinity material obtained from them. We could show that the specific activity of the isolated high affinity material is indistinguishable from that of the original materials when corrected for the non-affine material. We define the specific anti-thrombin activity as the increase of the pseudo-first order decay constant of endogenous thrombin in normal plasma brought about by 1 pg/ml of heparin. (Alternatively, with heparin preparations of well defined molecular weight, one can express the specific activity per nanomole.) If the specific activity were constant with unit weight this would mean that the catalytic activity of a heparin molecule increases proportionally with its length, if it would be constant per molar unit this would indicate that being longer than 18 monosaccharide units is a necessary and sufficient condition for a heparin molecule to express full antithrombin activity. Table 3 gives the specific activities found. It is confirmed that only the fractions with a chainlength > 18 saccharide units possess anti-thrombin activity. The. heparins without significant antithrombin activity (fractions N6-N14) we call P-type heparins, the others S-type heparins (16) . Within the S-type group, no significant systematic variation of the specific activity can be observed with the chainlength, neither when expressed on a weight-or on a molar basis. The data do not allow to distinguish between these two possibilities. A larger series of heparins with well defined chainlengths between 20 and 40 monosaccharide units will have to be available to settle that question.
The Inhibition of Prothrombin Conversion
The inhibition of extrinsic prothrombinase is a consequence of the inactivation of factor Xa. The inhibition of the intrinsic prothrombinase is a combined effect of factor Xa inactivation and inhibition of factor X activation (see below). The IC25 values for extrinsic prothrombinase inhibition, even when corrected for the non-affine material present, are lower for the S type heparins than for the P type materials. This is already clear when expressed on a weight basis and it is even more evident when they are expressed in molar units (Table 4 ). This shows that in plasma, in the presence of Ca2+ ions, the medium molecular weight heparin species are more potent inhibitors of factor Xa than the ultra-low species are. This was also observed in a purified system (31, 32) . Within the S or the P group no systematic shift of the activity with the molecular weight can be observed. It is rather as if the difference that brings about the anti-thrombin activity also increases the antiprothrombinase (i. e. anti-factor Xa) activity. Table 4 suggests that the effect of the higher molecular weight species (> N20) in enoxaparin on intrinsic prothrombinase activity is more important than on the extrinsic one. This can be explained by their antithrombin activity, on the thrombin dependent feedback activation of factor VIII (12, 16,34:36) . This not only causes a prolongation of the lag-phase (Fig.5 ) but also prevents factor IXa from being protected by factor VIIIa, so that it is inactivated by AT Ill-heparin and less prothombinase is formed. This mechanism has been shown to be operative with unfractionated heparin (37) .
The Overall Inhibition of the Thrombin Peak
The inhibition of the thrombin peak is the combined effect of inhibition of prothrombin conversion and enhancement of thrombin breakdown. Within the P group IC25 for thrombin inhibition is equal to that of prothrombinase inhibition, which is a logical consequence of their acting through inhibition of prothrombin conversion only. The value scatters around 100 nM (Table 4) .
In the S group the concentration necessary to inhibit for 25o/o the thrombin peak is 2 to 4 times lower than that required to obtain a similar inhibition of prothrombinase. This indicates that the main effect of the S-type heparin is on thrombin breakdown and that their anti-factor Xa activity, although definitely present, does not contribute much to the overall inhibition of the thrombin peak. Comparison of the IC25 values of the original enoxaparin and the fractions N6-N36 shows that the molecular soecies <6,000 are hardly active in thrombin inhibition. Because of the limited amount of material with MW >9,000 in enoxaparin, we must conclude that the main active species must be thought to have a chainlength of between 20 and 30 saccharide units.
Our findings pertain to the question of the importance for a LMWH to have an anti-factor Xa activity. Ever since Yn (38) suggested that, to obtain adequate anticoagulation, inhibition of factor Xa might be a more efficient means than inhibiting thrombin, this idea has persisted in the literature (e.g. ref. 7) . In fact, because factor Xa is only one of the three components of the prothrombin activating enzyme (39, 40) , and because, under the conditions in clotting plasma it is not the rate limiting component (16) , inhibition of factor Xa is an inefficient way of inhibiting thrombin generation (12, 14, 40) .
It follows from our results that a considerable amount of the activity of enoxaparin, like that of unfractionated heparin, is due to its anti-thrombin properties. It is likely to be irrelevant for the antithrombotic activity whether the generation of thrombin is inhibited or its inactivation enhanced. This seems to be in accordance with results obtained in experimental thrombosis in animals (1 and references therein). The fact that both oral anticoagulation and heparin treatment are effective antithrombotic strategies, although acting by completely different mechanisms, points in that direction. Probably the clinical efficacy of a LMWH is determined by a compromise between inhibitory properties, that become more pronounced with higher MW, and pharmacokinetical proterties such as half-life time and bioavailability, that are more favourable in smaller molecules.
